Table 6 The association of fish oil with VAF
From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure
Author | Design | N (Control) | Exposure Timing | Outcome (duration) | VAF development |
|---|---|---|---|---|---|
Schmitz et al [81] | Placebo-controlled | 24 (12) | Omega-3 4 g/day Post | Primary patency rates of AVG (1 year) | Lower risk (75.6 % vs. 14.9%, P < 0.03) |
Lok et al [80] | Placebo-controlled | 201 (100) | Omega-3 4 g/day Post | Primary AVG failure (1000 days) | Lower risk (3.43% vs. 5.95%, HR 0.58, 95% CI 0.44–0.75, P < 0.001) |
Irish et al [68] | Placebo-controlled | 567 (283) | Omega-3 4 g/day Pre | Primary AVF failure (12 months) | Equivalent risk (22% vs. 23%, RR 0.98, 95% CI 0.72–1.34, P = 0.90) |